Pfizer: 2026 Feels Like Another Lost Year After Yesterday's Guidance Update [Seeking Alpha]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Seeking Alpha
PFE faces major patent expiries, declining COVID franchise revenues, and high debt, all weighing on near-term growth prospects and valuation. The Metsera obesity drug acquisition offers a potential 2026 catalyst, but efficacy and competitive differentiation remain unproven and high risk. Despite a sector-leading 6.75% dividend yield, management signals capital allocation will prioritize business reinvestment over near-term dividend growth. JHVEPhoto/iStock Editorial via Getty Images Investment Overview Yesterday, the Pharma giant Pfizer Inc. ( PFE ) took the unusual step of not only providing its full-year 2025 revenue and earnings numbers, but also providing precise guidance for full-year 2026. Usually, companies share More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer: Ignoring The Dead Cat Bounce [Seeking Alpha]Seeking Alpha
- Pfizer (NYSE:PFE) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility [Yahoo! Finance]Yahoo! Finance
- Pfizer (NYSE:PFE) was given a new $24.00 price target on by analysts at Wolfe Research. They now have an "underperform" rating on the stock.MarketBeat
- PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin EligibilityPR Newswire
PFE
Earnings
- 11/4/25 - Beat
PFE
Sec Filings
- 12/16/25 - Form 8-K
- 12/2/25 - Form 4
- 11/21/25 - Form 8-K
- PFE's page on the SEC website